vs

Side-by-side financial comparison of CITIZENS, INC. (CIA) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $72.1M, roughly 1.2× CITIZENS, INC.). CITIZENS, INC. runs the higher net margin — 10.2% vs -38.1%, a 48.2% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 13.5%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 11.7%).

Citizen Watch Co., Ltd. , also known as the Citizen Group, is an electronics company primarily known for its watches and is the core company of a Japanese global corporate group based in Nishitokyo, Tokyo, Japan. In addition to Citizen brand watches, it is the parent of American watch company Bulova. Beyond watches, Citizen also manufactures calculators, printers, health care devices, and precision CNC machining equipment.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

CIA vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.2× larger
PRCT
$83.1M
$72.1M
CIA
Growing faster (revenue YoY)
PRCT
PRCT
+6.7% gap
PRCT
20.2%
13.5%
CIA
Higher net margin
CIA
CIA
48.2% more per $
CIA
10.2%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
11.7%
CIA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CIA
CIA
PRCT
PRCT
Revenue
$72.1M
$83.1M
Net Profit
$7.3M
$-31.6M
Gross Margin
64.9%
Operating Margin
10.9%
-4.1%
Net Margin
10.2%
-38.1%
Revenue YoY
13.5%
20.2%
Net Profit YoY
102.7%
-27.9%
EPS (diluted)
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIA
CIA
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$72.1M
$76.4M
Q3 25
$62.8M
$83.3M
Q2 25
$65.1M
$79.2M
Q1 25
$55.7M
$69.2M
Q4 24
$63.5M
$68.2M
Q3 24
$61.7M
$58.4M
Q2 24
$62.1M
$53.4M
Net Profit
CIA
CIA
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$7.3M
$-29.8M
Q3 25
$2.4M
$-21.4M
Q2 25
$6.5M
$-19.6M
Q1 25
$-1.6M
$-24.7M
Q4 24
$3.6M
$-18.9M
Q3 24
$2.8M
$-21.0M
Q2 24
$4.0M
$-25.6M
Gross Margin
CIA
CIA
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
CIA
CIA
PRCT
PRCT
Q1 26
-4.1%
Q4 25
10.9%
-40.6%
Q3 25
7.1%
-27.8%
Q2 25
10.6%
-28.0%
Q1 25
-3.2%
-39.7%
Q4 24
5.9%
-28.9%
Q3 24
4.9%
-38.4%
Q2 24
5.3%
-50.3%
Net Margin
CIA
CIA
PRCT
PRCT
Q1 26
-38.1%
Q4 25
10.2%
-39.1%
Q3 25
3.8%
-25.7%
Q2 25
9.9%
-24.7%
Q1 25
-2.9%
-35.8%
Q4 24
5.7%
-27.6%
Q3 24
4.5%
-35.9%
Q2 24
6.4%
-48.0%
EPS (diluted)
CIA
CIA
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$-0.54
Q3 25
$-0.38
Q2 25
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIA
CIA
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$23.0M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$235.0M
$347.7M
Total Assets
$1.8B
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIA
CIA
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$23.0M
$286.5M
Q3 25
$23.1M
$294.3M
Q2 25
$22.7M
$302.7M
Q1 25
$18.4M
$316.2M
Q4 24
$29.3M
$333.7M
Q3 24
$32.4M
$196.8M
Q2 24
$26.3M
$214.1M
Total Debt
CIA
CIA
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
CIA
CIA
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$235.0M
$365.9M
Q3 25
$225.6M
$380.3M
Q2 25
$229.0M
$385.8M
Q1 25
$218.1M
$389.2M
Q4 24
$210.4M
$402.2M
Q3 24
$207.6M
$241.2M
Q2 24
$191.5M
$251.8M
Total Assets
CIA
CIA
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$1.8B
$508.1M
Q3 25
$1.7B
$511.5M
Q2 25
$1.7B
$513.1M
Q1 25
$1.7B
$519.4M
Q4 24
$1.7B
$534.0M
Q3 24
$1.7B
$374.1M
Q2 24
$1.7B
$374.4M
Debt / Equity
CIA
CIA
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIA
CIA
PRCT
PRCT
Operating Cash FlowLast quarter
$18.0M
Free Cash FlowOCF − Capex
$17.5M
FCF MarginFCF / Revenue
24.3%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
2.45×
TTM Free Cash FlowTrailing 4 quarters
$26.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIA
CIA
PRCT
PRCT
Q1 26
Q4 25
$18.0M
$-10.3M
Q3 25
$4.7M
$-6.6M
Q2 25
$3.5M
$-15.0M
Q1 25
$748.0K
$-17.0M
Q4 24
$31.9M
$-32.4M
Q3 24
$9.7M
$-18.8M
Q2 24
$4.6M
$-15.7M
Free Cash Flow
CIA
CIA
PRCT
PRCT
Q1 26
Q4 25
$17.5M
$-12.2M
Q3 25
$4.6M
$-9.5M
Q2 25
$3.3M
$-17.8M
Q1 25
$641.0K
$-18.8M
Q4 24
$31.3M
$-33.6M
Q3 24
$9.3M
$-19.0M
Q2 24
$4.5M
$-16.8M
FCF Margin
CIA
CIA
PRCT
PRCT
Q1 26
Q4 25
24.3%
-15.9%
Q3 25
7.3%
-11.4%
Q2 25
5.1%
-22.5%
Q1 25
1.2%
-27.2%
Q4 24
49.2%
-49.2%
Q3 24
15.1%
-32.6%
Q2 24
7.2%
-31.4%
Capex Intensity
CIA
CIA
PRCT
PRCT
Q1 26
Q4 25
0.6%
2.4%
Q3 25
0.1%
3.4%
Q2 25
0.3%
3.5%
Q1 25
0.2%
2.7%
Q4 24
1.0%
1.7%
Q3 24
0.6%
0.4%
Q2 24
0.2%
2.0%
Cash Conversion
CIA
CIA
PRCT
PRCT
Q1 26
Q4 25
2.45×
Q3 25
1.93×
Q2 25
0.54×
Q1 25
Q4 24
8.81×
Q3 24
3.48×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CIA
CIA

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons